Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNJ1 | P48048 | 20/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.54 |
| ▸ | ACHE | P22303 | 1/20 | 0.54 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.54 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15017995 | 1.00 | KCNJ1 (0.56) | KCNJ1KCNH2ACHESSTR1SLC6A4 | |
| SCHEMBL15879145 | 1.00 | KCNJ1 (0.56) | KCNJ1KCNH2ACHESSTR1SLC6A4 | |
| SCHEMBL15879599 | 1.00 | KCNJ1 (0.56) | KCNJ1KCNH2ACHESSTR1SLC6A4 | |
| SCHEMBL15879143 | 1.00 | KCNJ1 (0.56) | KCNJ1KCNH2ACHESSTR1SLC6A4 | |
| SCHEMBL14719838 | 1.00 | KCNJ1 (0.56) | KCNJ1KCNH2ACHESSTR1SLC6A4 | |
| SCHEMBL15878953 | 0.93 | KCNJ1 (0.54) | KCNJ1KCNH2ACHESSTR1SLC6A4 | |
| SCHEMBL16227797 | 0.90 | KCNJ1 (0.52) | KCNJ1KCNH2ACHESSTR1SLC6A4 | |
| SCHEMBL15879153 | 0.90 | KCNJ1 (0.52) | KCNJ1KCNH2ACHESSTR1SLC6A4 | |
| SCHEMBL15879150 | 0.90 | KCNJ1 (0.52) | KCNJ1KCNH2ACHESSTR1SLC6A4 | |
| SCHEMBL15879149 | 0.90 | KCNJ1 (0.52) | KCNJ1KCNH2ACHESSTR1SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2748166-A1 | PYRIMIDO- PYRIDAZINONE COMPOUNDS AND USE THEREOF | Endo Pharmaceuticals Inc. (US) | 2014-07-02 | — | — | EP | claimed |
| WO-2013028818-A1 | PYRIMIDO- PYRIDAZINONE COMPOUNDS AND USE THEREOF | ENDO PHARMACEUTICALS INC. (US) | 2013-02-28 | — | — | WO | claimed |
| EP-2934533-B1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME (US) | 2017-11-15 | — | — | EP | disclosed |
| EP-2956142-B1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME (US) | 2017-09-20 | — | — | EP | disclosed |
| US-9604998-B2 | Inhibitors of the renal outer medullary potassium channel | MERCK SHARP & DOHME CORP. (US) | 2017-03-28 | — | — | US | disclosed |
| US-9573961-B2 | Inhibitors of the renal outer medullary potassium channel | MERCK SHARP & DOHME CORP. (US) | 2017-02-21 | — | — | US | disclosed |
| EP-2744499-B1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME (US) | 2016-09-28 | — | — | EP | disclosed |
| EP-2790511-B1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME (US) | 2016-09-14 | — | — | EP | disclosed |
| US-20160002259-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME CORP. (US) | 2016-01-07 | — | — | US | disclosed |
| US-9206199-B2 | Inhibitors of the renal outer medullary potassium channel | MERCK SHARP & DOHME CORP. (US) | 2015-12-08 | — | — | US | disclosed |
| US-20150329557-A1 | Inhibitors of the Renal Outer Medullary Potassium Channel | MERCK SHARP & DOHME CORP. (US) | 2015-11-19 | — | — | US | disclosed |
| US-9062070-B2 | Inhibitors of the renal outer medullary potassium channel | MERCK SHARP & DOHME CORP. (US) | 2015-06-23 | — | — | US | disclosed |
| US-20140336177-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME LLC | 2014-11-13 | — | — | US | disclosed |
| EP-2790511-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | Merck Sharp & Dohme Corp. (US) | 2014-10-22 | — | — | EP | disclosed |
| US-20140206618-A1 | Inhibitors of the Renal Outer Medullary Potassium Channel | MERCK SHARP & DOHME LLC | 2014-07-24 | — | — | US | disclosed |
| WO-2013090271-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME CORP. (US) | 2013-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150329557-A1 | Inhibitors of the Renal Outer Medullary Potassium Channel | KCNJ11, KCNJ1, KCNJ2 | KCNJ1 2/4885KCNH2 22/4885ACHE 4856/4885 |
| US-20140206618-A1 | Inhibitors of the Renal Outer Medullary Potassium Channel | KCNJ11, KCNJ1, KCNJ2 | KCNJ1 2/4885KCNH2 16/4885ACHE 4849/4885 |
| US-20140336177-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | KCNJ11, KCNJ1, KCNJ2 | KCNJ1 2/4885KCNH2 21/4885ACHE 4829/4885 |
| US-20160002259-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | KCNJ11, KCNJ1, KCNJ2 | KCNJ1 2/4885KCNH2 21/4885ACHE 4845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.